Johnson & Johnson logo

Johnson & Johnson (JNJ)

Market Closed
5 Dec, 20:00
NYSE NYSE
$
201. 93
-0.55
-0.27%
$
500.07B Market Cap
29.06 P/E Ratio
4.96% Div Yield
6,935,279 Volume
9.91 Eps
$ 202.48
Previous Close
Day Range
200.81 203.45
Year Range
140.68 207.81
Want to track JNJ and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!
Earnings results expected in 46 days
Johnson & Johnson (JNJ) Ascends But Remains Behind Market: Some Facts to Note

Johnson & Johnson (JNJ) Ascends But Remains Behind Market: Some Facts to Note

In the most recent trading session, Johnson & Johnson (JNJ) closed at $145.27, indicating a +0.55% shift from the previous trading day.

Zacks | 11 months ago
Why Investors Need to Take Advantage of These 2 Medical Stocks Now

Why Investors Need to Take Advantage of These 2 Medical Stocks Now

The Zacks Earnings ESP is a great way to find potential earnings surprises. Why investors should take advantage now.

Zacks | 11 months ago
Johnson & Johnson: Dividend Legend At A Discount

Johnson & Johnson: Dividend Legend At A Discount

Johnson & Johnson's diversified revenue streams, significant presence in oncology and immunotherapy, and aggressive growth investments make it a strong defensive play. The company's low leverage, ample liquidity, and impressive free cash flow margin support its dividend sustainability and long-term growth. The stock is very attractively valued with an 18% potential upside.

Seekingalpha | 11 months ago
Health Rounds: J&J drug helps delay multiple myeloma in high-risk patients

Health Rounds: J&J drug helps delay multiple myeloma in high-risk patients

The Johnson & Johnson drug Darzalex showed promise in helping keep a precancerous condition from progressing to the blood cancer multiple myeloma for those at high risk, according to results from a trial presented at the American Society of Hematology meeting in San Diego.

Reuters | 11 months ago
Johnson & Johnson (JNJ) Stock Declines While Market Improves: Some Information for Investors

Johnson & Johnson (JNJ) Stock Declines While Market Improves: Some Information for Investors

In the most recent trading session, Johnson & Johnson (JNJ) closed at $143.85, indicating a -1.89% shift from the previous trading day.

Zacks | 11 months ago
US FDA declines to approve injection form of J&J's lung cancer drug

US FDA declines to approve injection form of J&J's lung cancer drug

The U.S. Food and Drug Administration has declined to approve an injectable version of Johnson & Johnson's drug Rybrevant for a type of lung cancer, the drugmaker said on Monday.

Reuters | 11 months ago
Johnson & Johnson (JNJ) Is a Trending Stock: Facts to Know Before Betting on It

Johnson & Johnson (JNJ) Is a Trending Stock: Facts to Know Before Betting on It

Recently, Zacks.com users have been paying close attention to Johnson & Johnson (JNJ). This makes it worthwhile to examine what the stock has in store.

Zacks | 11 months ago
Johnson & Johnson Just Paid Investors: Here's How Much They Received

Johnson & Johnson Just Paid Investors: Here's How Much They Received

Johnson & Johnson (NYSE: JNJ) is rewarding its shareholders once again with a quarterly dividend of $1.24, payable on Tuesday, Dec.

247wallst | 0 year ago
Johnson & Johnson (JNJ) Stock Slides as Market Rises: Facts to Know Before You Trade

Johnson & Johnson (JNJ) Stock Slides as Market Rises: Facts to Know Before You Trade

In the most recent trading session, Johnson & Johnson (JNJ) closed at $150.47, indicating a -1.24% shift from the previous trading day.

Zacks | 1 year ago
J&J Seeks FDA Approval for Tremfya for Psoriasis in Kids

J&J Seeks FDA Approval for Tremfya for Psoriasis in Kids

Johnson & Johnson JNJ announced that it has filed two supplemental biologics license applications (sBLA) seeking expanded use of its drug Tremfya in pediatric patients.

Zacks | 1 year ago
Investors Heavily Search Johnson & Johnson (JNJ): Here is What You Need to Know

Investors Heavily Search Johnson & Johnson (JNJ): Here is What You Need to Know

Zacks.com users have recently been watching Johnson & Johnson (JNJ) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.

Zacks | 1 year ago
How To Build A $25,000 Dividend Portfolio, Johnson & Johnson As Your Core Holding

How To Build A $25,000 Dividend Portfolio, Johnson & Johnson As Your Core Holding

Johnson & Johnson offers investors an effective combination of dividend income and dividend growth, evidenced by its Dividend Yield [TTM] of 3.13% and 5-Year Dividend Growth Rate [CAGR] of 5.61%. The company from the Pharmaceuticals Industry, which has an Aaa credit rating from Moody's, can serve as a strategically important core-position within your dividend portfolio. Allocating the largest proportion of your dividend portfolio to Johnson & Johnson can position your portfolio for reduced volatility and help to decrease its overall risk level.

Seekingalpha | 1 year ago
Loading...
Load More